Patients with multiple sclerosis had higher cortisol levels than healthy controls, with slightly higher levels in those with multiple sclerosis without than with fatigue.
Disease course, fatigue, self-efficacy, and diet and exercise are major determinants of unemployment for patients with MS.
12-item Multiple Sclerosis Walking Scale items offer insight into mobility of mildly and moderately-severely disabled patients with multiple sclerosis.
In patients with active relapses in secondary progressive multiple sclerosis, disease-modifying therapies improved disability outcomes.
Early, continuous ocrelizumab was related to a sustained reduction of relapsing MS progression compared with patients who switched from IFN β-1a.
The researchers found that the mean age at CIS onset was 31.5 years. Before CIS onset, 46 percent of women had at least one pregnancy and 43 percent had at least one childbirth.
Compared to teriflunomide, ponesimod showed benefit for magnetic resonance imaging (MRI) outcomes in relapsing multiple sclerosis.
ADS-5102, the extended release capsule form of amantadine, may clinically benefit walking speed in patients with multiple sclerosis.
In secondary progressive multiple sclerosis, amiloride, fluoxetine, and rizuole treatments do not translate into long-term reduction in atrophy rates.
Baseline levels of ubiquitin C-terminal hydrolase L1 in cerebral spinal fluid may be predictive of long term multiple sclerosis progression.